Short answer
Immunome Inc. (IMNM) filed its Q2 2026 10-Q quarterly report on Aug 11, 2026 for the quarter ended Jun 30, 2026. Quarterly revenue was $0 (down 100.0% year over year) with net income of −$73M.
Q2 2026 key financials · XBRL
- Revenue
- $0
- −100.0% YoY
- Net income
- −$73M
- −68.5% YoY · −35.8% QoQ
- EPS (diluted)
- −$0.64
- −28.0% YoY · −33.3% QoQ
Source: XBRL data from the Immunome Inc. (IMNM) Q2 2026 10-Q on SEC EDGAR. USD.
Immunome Inc. Q2 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Risk Factors
- NDA review risk: Varegacestat application accepted with FDA PDUFA target action date of April 28, 2027
- Regulatory compliance risk: FDA may require additional trials, narrower labeling, REMS, or post-marketing studies
- Clinical execution risk: Three early-stage assets remain in Phase 1, including IM-1021, IM-1617, and IM-3050
- Liquidity risk: Cash, cash equivalents, and marketable securities expected to fund operations for at least 12 months
- Financial loss risk: Accumulated deficit reached $855.1 million as of June 30, 2026
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Immunome Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.